[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Neppl-Huber, C., Zappa, M., Coebergh, J.W., et al. (2012) Changes in Incidence, Survival and Mortality of Prostate Cancer in Europe and the United States in the PSA Era: Additional Diagnoses and Avoided Deaths. Annals of Oncology, 23, 1325-1334. https://doi.org/10.1093/annonc/mdr414
|
[3]
|
Resnick, M.J., Koyama, T., Fan, K.H., et al. (2013) Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer. The New England Journal of Medicine, 368, 436-445. https://doi.org/10.1056/NEJMoa1209978
|
[4]
|
Godtman, R.A., Kollberg, K.S., Pihl, C.G., et al. (2022) The Association between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-Term Screening Program: Results from the Göteborg-1 Prostate Cancer Screening Trial. European Urology, 82, 311-317. https://doi.org/10.1016/j.eururo.2022.01.018
|
[5]
|
Sekhoacha, M., Riet, K., Motloung, P., et al. (2022) Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules, 27, Article 5730. https://doi.org/10.3390/molecules27175730
|
[6]
|
Fernández-Anguita, P.J., Ventosa-Puig, M., Díaz De Mera-Sánchez Migallón, I., et al. (2023) Value of Prostate-Specific Antigen Kinetics in Patients with Low-Risk Prostate Cancer under Active Surveillance. Urologia Internationalis, 107, 706-712. https://doi.org/10.1159/000530963
|
[7]
|
Goluboff, E.T., Heitjan, D.F., Devries, G.M., et al. (1997) Pretreatment Prostate Specific Antigen Doubling Times: Use in Patients before Radical Prostatectomy. Journal of Urology, 158, 1876-1878. https://doi.org/10.1016/S0022-5347(01)64154-5
|
[8]
|
Egawa, S., Arai, Y., Tobisu, K., et al. (2000) Use of Pretreatment Prostate-Specific Antigen Doubling Time to Predict Outcome after Radical Prostatectomy. Prostate Cancer and Prostatic Diseases, 3, 269-274. https://doi.org/10.1038/sj.pcan.4500424
|
[9]
|
Schaeffer, E.M., Srinivas, S., Adra, N., et al. (2023) Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. The National Comprehensive Cancer Network, 21, 1067-1096. https://doi.org/10.6004/jnccn.2023.0050
|
[10]
|
Naji, L., Randhawa, H., Sohani, Z., et al. (2018) Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis. The Annals of Family Medicine, 16, 149-154. https://doi.org/10.1370/afm.2205
|
[11]
|
Herrera-Caceres, J.O., Wettstein, M.S., Goldberg, H., et al. (2020) Utility of Digital Rectal Examination in a Population with Prostate Cancer Treated with Active Surveillance. Canadian Urological Association Journal, 14, E453-E457. https://doi.org/10.5489/cuaj.6341
|
[12]
|
Mottet, N., Van Den Bergh, R.C.N., Briers, E., et al. (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 79, 243-262. https://doi.org/10.1016/j.eururo.2020.09.042
|
[13]
|
Mottet, N., Bellmunt, J., Bolla, M., et al. (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 71, 618-629. https://doi.org/10.1016/j.eururo.2016.08.003
|
[14]
|
Hodge, K.K., Mcneal, J.E. and Stamey, T.A. (1989) Ultrasound Guided Transrectal Core Biopsies of the Palpably Abnormal Prostate. Journal of Urology, 142, 66-70. https://doi.org/10.1016/S0022-5347(17)38663-9
|
[15]
|
Boesen, L. (2017) Multiparametric MRI in Detection and Staging of Prostate Cancer. Danish Medical Journal, 64, B5327.
|
[16]
|
Lee, D.J., Recabal, P., Sjoberg, D.D., et al. (2016) Comparative Effectiveness of Targeted Prostate Biopsy Using Magnetic Resonance Imaging Ultrasound Fusion Software and Visual Targeting: A Prospective Study. Journal of Urology, 196, 697-702. https://doi.org/10.1016/j.juro.2016.03.149
|
[17]
|
Castellucci, R., Linares Quevedo, A.I., Sánchez Gómez, F.J., et al. (2017) Prospective Nonrandomized Study of Diagnostic Accuracy Comparing Prostate Cancer Detection by Transrectal Ultrasound-Guided Biopsy to Magnetic Resonance Imaging with Subsequent MRI-Guided Biopsy in Biopsy-Naïve Patients. Minerva Urology and Nephrology, 69, 589-595. https://doi.org/10.23736/S0393-2249.17.02845-4
|
[18]
|
Delongchamps, N.B., Peyromaure, M., Schull, A., et al. (2013) Prebiopsy Magnetic Resonance Imaging and Prostate Cancer Detection: Comparison of Random and Targeted Biopsies. Journal of Urology, 189, 493-499. https://doi.org/10.1016/j.juro.2012.08.195
|
[19]
|
Kam, J., Yuminaga, Y., Kim, R., et al. (2018) Does Magnetic Resonance Imaging-Guided Biopsy Improve Prostate Cancer Detection? A Comparison of Systematic, Cognitive Fusion and Ultrasound Fusion Prostate Biopsy. Prostate International, 6, 88-93. https://doi.org/10.1016/j.prnil.2017.10.003
|
[20]
|
Wegelin, O., Exterkate, L., Van Der Leest, M., et al. (2019) The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. European Urology, 75, 582-590. https://doi.org/10.1016/j.eururo.2018.11.040
|
[21]
|
Elkhoury, F.F., Felker, E.R., Kwan, L., et al. (2019) Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. JAMA Surgery, 154, 811-818. https://doi.org/10.1001/jamasurg.2019.1734
|
[22]
|
Hugosson, J., Månsson, M., Wallström, J., et al. (2022) Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. The New England Journal of Medicine, 387, 2126-2137. https://doi.org/10.1056/NEJMoa2209454
|
[23]
|
Frye, T.P., George, A.K., Kilchevsky, A., et al. (2017) Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. Journal of Urology, 197, 640-646. https://doi.org/10.1016/j.juro.2016.08.109
|
[24]
|
Schoots, I.G., Nieboer, D., Giganti, F., et al. (2018) Is Magnetic Resonance Imaging-Targeted Biopsy a Useful Addition to Systematic Confirmatory Biopsy in Men on Active Surveillance for Low-Risk Prostate Cancer? A Systematic Review and Meta-Analysis. BJU International, 122, 946-958. https://doi.org/10.1111/bju.14358
|
[25]
|
Hamoen, E.H.J., Hoeks, C.M.A., Somford, D.M., et al. (2019) Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-Guided Biopsies in Men with Low-Risk Prostate Cancer on Active Surveillance after 1 Yr Follow-Up. European Urology Focus, 5, 407-415. https://doi.org/10.1016/j.euf.2017.12.008
|
[26]
|
Pepe, P., Pepe, L., Pennisi, M., et al. (2022) Confirmatory Transperineal Saturation Prostate Biopsy Combined with MpMRI Decrease the Reclassification Rate in Men Enrolled in Active Surveillance: Our Experience in 100 Men Submitted to Eight-Years Scheduled Biopsy. Archivio Italiano Di Urologia E Andrologia, 94, 270-273. https://doi.org/10.4081/aiua.2022.3.270
|
[27]
|
Dieffenbacher, S., Nyarangi-Dix, J., Giganti, F., et al. (2021) Standardized Magnetic Resonance Imaging Reporting Using the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Criteria and Magnetic Resonance Imaging/Transrectal Ultrasound Fusion with Transperineal Saturation Biopsy to Select Men on Active Surveillance. European Urology Focus, 7, 102-110. https://doi.org/10.1016/j.euf.2019.03.001
|
[28]
|
中华医学会男科学分会, 前列腺穿刺活检专家共识编写组. 前列腺穿刺活检专家共识[J]. 中华男科学杂志, 2022, 28(5): 462-470.
|
[29]
|
顾伟杰, 朱耀. 2022版《CSCO前列腺癌诊疗指南》更新要点解读[J]. 中国肿瘤外科杂志, 2022, 14(3): 224-232.
|
[30]
|
Borghesi, M., Bianchi, L., Barbaresi, U., et al. (2021) Diagnostic Performance of MRI/TRUS Fusion-Guided Biopsies vs. Systematic Prostate Biopsies in Biopsy-Naïve, Previous Negative Biopsy Patients and Men Undergoing Active Surveillance. Minerva Urology and Nephrology, 73, 357-366. https://doi.org/10.23736/S2724-6051.20.03758-3
|
[31]
|
Benelli, A., Vaccaro, C., Guzzo, S., et al. (2020) The Role of MRI/TRUS Fusion Biopsy in the Diagnosis of Clinically Significant Prostate Cancer. Therapeutic Advances in Urology, 12. https://doi.org/10.1177/1756287220916613
|
[32]
|
Moore, C.M., King, L.E., Withington, J., et al. (2023) Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting. European Urology Oncology, 6, 160-182. https://doi.org/10.1016/j.euo.2023.01.003
|
[33]
|
王立鹏, 阳青松, 张威, 等. 多参数磁共振成像在前列腺癌中的诊断价值[J]. 第二军医大学学报, 2019, 40(11): 1236-1241.
|
[34]
|
Ploussard, G., Rouvière, O., Rouprêt, M., et al. (2022) The Current Role of MRI for Guiding Active Surveillance in Prostate Cancer. Nature Reviews Urology, 19, 357-365. https://doi.org/10.1038/s41585-022-00587-0
|
[35]
|
Greenberg, J.W., Koller, C.R., Lightfoot, C., et al. (2024) Annual MpMRI Surveillance: PI-RADS Upgrading and Increasing Trend Correlated with Patients Who Harbor Clinically Significant Disease. Urologic Oncology: Seminars and Original Investigations. https://doi.org/10.1016/j.urolonc.2024.01.005
|
[36]
|
Schmid, F.A., Lieger, L., Saba, K., et al. (2023) Therapy Decisions after Diagnosis of Prostate Cancer in Men with Negative Prostate MRI. Prostate, 83, 56-63. https://doi.org/10.1002/pros.24435
|
[37]
|
Zhai, L., Fan, Y., Meng, Y., et al. (2019) The Role of Prostate Imaging Reporting and Data System Score in Gleason 3 3 Active Surveillance Candidates Enrollment: A Diagnostic Meta-Analysis. Prostate Cancer and Prostatic Diseases, 22, 235-243. https://doi.org/10.1038/s41391-018-0111-4
|
[38]
|
Luiting, H.B., Remmers, S., Boevé, E.R., et al. (2022) A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-Based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study. European Urology Oncology, 5, 651-658. https://doi.org/10.1016/j.euo.2022.03.007
|
[39]
|
Luzzago, S., Piccinelli, M.L., Mistretta, F.A., et al. (2022) Repeat MRI during Active Surveillance: Natural History of Prostatic Lesions and Upgrading Rates. BJU International, 129, 524-533. https://doi.org/10.1111/bju.15623
|
[40]
|
Nguyen, T.A., Fourcade, A., Zambon, A., et al. (2023) Optimal PSA Density Threshold and Predictive Factors for the Detection of Clinically Significant Prostate Cancer in Patient with a PI-RADS 3 Lesion on MRI. Urologic Oncology: Seminars and Original Investigations, 41, 354.e11-354.e18. https://doi.org/10.1016/j.urolonc.2023.05.005
|
[41]
|
Wang, C., Yuan, L., Shen, D., et al. (2022) Combination of PI-RADS Score and PSAD Can Improve the Diagnostic Accuracy of Prostate Cancer and Reduce Unnecessary Prostate Biopsies. Frontiers in Oncology, 12, Article 1024204. https://doi.org/10.3389/fonc.2022.1024204
|
[42]
|
Moore, C.M., Giganti, F., Albertsen, P., et al. (2017) Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations—A Report of a European School of Oncology Task Force. European Urology, 71, 648-655. https://doi.org/10.1016/j.eururo.2016.06.011
|
[43]
|
Bhanji, Y., Mamawala, M., De La Calle, C.M., et al. (2023) Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) Magnetic Resonance Imaging Scoring to Predict Clinical Outcomes in Active Surveillance for Grade Group 1 Prostate Cancer. Urology, 180, 194-199. https://doi.org/10.1016/j.urology.2023.07.019
|
[44]
|
Caglic, I., Sushentsev, N., Gnanapragasam, V.J., et al. (2021) MRI-Derived PRECISE Scores for Predicting Pathologically-Confirmed Radiological Progression in Prostate Cancer Patients on Active Surveillance. European Radiology, 31, 2696-2705. https://doi.org/10.1007/s00330-020-07336-0
|
[45]
|
Aerts, J., Hendrickx, S., Berquin, C., et al. (2023) Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. European Urology Open Science, 56, 39-46. https://doi.org/10.1016/j.euros.2023.08.006
|
[46]
|
O’connor, L.P., Wang, A.Z., Yerram, N.K., et al. (2021) Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance. European Urology Oncology, 4, 227-234. https://doi.org/10.1016/j.euo.2020.09.004
|
[47]
|
Silver, D.A., Pellicer, I., Fair, W.R., et al. (1997) Prostate-Specific Membrane Antigen Expression in Normal and Malignant Human Tissues. Clinical Cancer Research, 3, 81-85.
|
[48]
|
Bostwick, D.G., Pacelli, A., Blute, M., et al. (1998) Prostate Specific Membrane Antigen Expression in Prostatic Intraepithelial Neoplasia and Adenocarcinoma: A Study of 184 Cases. Cancer, 82, 2256-2261. https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S
|
[49]
|
Eiber, M., Weirich, G., Holzapfel, K., et al. (2016) Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. European Urology, 70, 829-836. https://doi.org/10.1016/j.eururo.2015.12.053
|
[50]
|
Borque-Fernando, Á., Rubio-Briones, J., Esteban, L.M., et al. (2019) Role of the 4Kscore Test as a Predictor of Reclassification in Prostate Cancer Active Surveillance. Prostate Cancer and Prostatic Diseases, 22, 84-90. https://doi.org/10.1038/s41391-018-0074-5
|
[51]
|
Lin, D.W., Newcomb, L.F., Brown, M.D., et al. (2017) Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-Grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study. European Urology, 72, 448-454. https://doi.org/10.1016/j.eururo.2016.11.017
|
[52]
|
Eure, G., Germany, R., Given, R., et al. (2017) Use of a 17-Gene Prognostic Assay in Contemporary Urologic Practice: Results of an Interim Analysis in an Observational Cohort. Urology, 107, 67-75. https://doi.org/10.1016/j.urology.2017.02.052
|
[53]
|
Tosoian, J.J., Patel, H.D., Mamawala, M., et al. (2017) Longitudinal Assessment of Urinary PCA3 for Predicting Prostate Cancer Grade Reclassification in Favorable-Risk Men during Active Surveillance. Prostate Cancer and Prostatic Diseases, 20, 339-342. https://doi.org/10.1038/pcan.2017.16
|
[54]
|
Cantiello, F., Russo, G.I., Cicione, A., et al. (2016) PHI and PCA3 Improve the Prognostic Performance of PRIAS and Epstein Criteria in Predicting Insignificant Prostate Cancer in Men Eligible for Active Surveillance. World Journal of Urology, 34, 485-493. https://doi.org/10.1007/s00345-015-1643-z
|
[55]
|
Cantiello, F., Russo, G.I., Ferro, M., et al. (2015) Prognostic Accuracy of Prostate Health Index and Urinary Prostate Cancer Antigen 3 in Predicting Pathologic Features after Radical Prostatectomy. Urologic Oncology: Seminars and Original Investigations, 33, 163.e15-163.e23. https://doi.org/10.1016/j.urolonc.2014.12.002
|
[56]
|
Alshalalfa, M., Verhaegh, G.W., Gibb, E.A., et al. (2017) Low PCA3 Expression Is a Marker of Poor Differentiation in Localized Prostate Tumors: Exploratory Analysis from 12,076 Patients. Oncotarget, 8, 50804-50813. https://doi.org/10.18632/oncotarget.15133
|
[57]
|
Kornberg, Z., Cooperberg, M.R., Cowan, J.E., et al. (2019) A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. Journal of Urology, 202, 702-709. https://doi.org/10.1097/JU.0000000000000290
|
[58]
|
Agrawal, V., Ma, X., Hu, J.C., et al. (2021) Active Surveillance for Men with Intermediate Risk Prostate Cancer. Journal of Urology, 205, 115-121. https://doi.org/10.1097/JU.0000000000001241
|
[59]
|
Eastham, J.A., Boorjian, S.A. and Kirkby, E. (2022) Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Journal of Urology, 208, 505-507. https://doi.org/10.1097/JU.0000000000002854
|